Press Releases

 
Press Releases
Date Title and Summary View
Sep 26, 2016 SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagno...
Sep 7, 2016 SALT LAKE CITY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the abili...
Sep 1, 2016 SALT LAKE CITY, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an informatics-based precision medicine company providing treatme...
Aug 30, 2016 SALT LAKE CITY, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City....
Aug 9, 2016 Total Revenues of $186.5 MillionAdjusted EPS of $0.36 and Diluted EPS of $0.32Company Issues Fiscal First-Quarter 2017 and Fiscal Year 2017 Financial Guidance   SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASD...
Aug 3, 2016 SALT LAKE CITY, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Jul 26, 2016 SALT LAKE CITY, July 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 9, 2016.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, wil...
Jul 11, 2016 SALT LAKE CITY and COLOGNE, Germany, July 11, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), in collaboration with researchers from the Institute of Cancer Research in London, today announced positive results for EndoPredict®, a second-generation prognostic gene expression test for breast cancer.  The study ...
Jun 29, 2016 SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today ...
Jun 10, 2016 SALT LAKE CITY, June 10, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatis...
Page:
1
... NextLast
= add release to Briefcase